focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
If you listened to the conference now they alluded to evaluating the antibody "tests", and depending on which ones are deemed successful will determine how many of the 3.5m tests they can use. i.e What they are saying is that they have received antibody tests from several different suppliers and will evaluate which ones are accurate. I'd imagine NCYT are one of a few being evaluated.
What is interesting is the partnership with YourGene - as suddenly the UK want's 3.5 million test kits available, and back in 2018 Yourgene announced that it had entered into a partnership with Abnova, the world’s largest monoclonal antibody manufacturer
"it is understood the MK facility is a large centralised laboratory where swabs from people all over the country who are showing symptoms will be sent for analysis.
This is in line with the promise made by Prime minister Boris Johnson last week that the UK would increase tests for Covid-19 from 5,000 a day to 25,000 a day. The most seriously ill patients and frontline staff in the NHS will be prioritised.
Highly specialised equipment called or polymerase chain reaction (PCR) machines are used to detect the presence of the Covid-19 virus. "
https://www.miltonkeynes.co.uk/health/coronavirus/national-coronavirus-testing-centre-opens-milton-keynes-2516931
Interesting that Novacyt spokesman on newsnight last night said even if you got every single manufacturer on the planet to make tests in the would still not meet world wide demand. I think that says all you need to hear on where this is going.
This is so funny this cycle - derampers come out and say 80p is overvalued, NCYT release RNS price jumps around but settles higher at 100p, derampers say 100p is overvalued, NCYT release RNS price jumps around settles higher at 140p. Derampers say 140p overvalued, NCYT release RNS price jumps around but settles around 170p....See a pattern in who are the wrong ones here. Can't wait for the next couple of RNS, repeat pattern.
Lots more updates to come, they will be pregnant with RNS's - I expect further manufacturing increases, massive sales increases, further tie ups with OEM's and whisper it quietly I wouldn't be surprised with an antibody test too..
It doesn't matter how many times its already bagged - its mcap is still low in comparison to the number of sales it will do. Jeez, why do some people bother investing. Look forward not back!
I will repeat the mcap is tiny for a world wide pandemic. They can sell to Europe, Indonesia, Philippines and have distributers for another 60 countries. Try adding up the potential market there. Manufacturing capacity is rapidly growing, multibillion US OEM now on board, and sales growing exponentially along sadly with the virus. If people can't see this will be 400-500m mcap in the coming weeks then more fool them.
Wow just logged on to see our OEM - ha ha brilliant, well done all holders. Those derampers hoping for cheaper entry gotta laugh. When will they learn this space is so hot at the moment and NCYT are doing all the right moves. Again and again and again this company over the last few months keeps proving itself. Brilliant.
Yep exactly - and I bet you they are looking at the antibody part test for cv19 - they are not a one trick pony, and have been one of the firsts to develop tests for cv19, sars, swine flu - they are very good at what they do.
Yep that is what I'm referring to in my post below about their serology team and the 15min flu antibody test - which you can see here
https://twitter.com/MicrogenBioProd/status/1239506074123853824
jgj99 - they are both equally important in dealing with the virus. France have recognised that PCR testing (NCYT's version) is the best as its the most accurate, if something is only 90% accurate its about as much use as a chocolate tea cup. Anitbody is great for testing who's had it, a combination of both is need to deal with this. NCYT also have a serology department - i.e Anitbody testing - they already have 15min antigen tests for Influenza. As with PCR tests there won't be just one, but I bet you that NCYT will have a part to play there too.
£115m mcap is nothing, PE of 10-20x is normal for pharma. They are going to be selling 2m tests a month minimum, and as demand is there capacity will increase accordingly "the Company also announces it is in advanced discussions with a second third-party manufacturer, based in the UK, in order to further expand manufacturing capacity." I full expect 3-4m tests to be reached and sold by end of April. Its obvious, just look at the sales figure increasing each week. Investing is about looking at the demand for a product, and growth for that business in the future. Well this future is here right now, demand increasing rapidly, capacity increasing massively, sales increasing massively. And lets not even mention the serology unit of NCYT that might deliver the antibody test also.
Every single country will want millions of testing kits, there are 198 countries in the world, a population of 7.7 billion. Most countries will want to test a reasonable % of that. Most of these countries will need supply from outside as they don't have the science or manufacturing to deal with this. Virtually all companies that supply good, accurate and reasonably priced tests will do well. Demand > supply. Simples.
Qiagen plans to increase testing to 6.5m tests by end of April, I'd imagine NCYT will be aiming for something similar. So many countries are going to need this for a considerable future. We can see from the last RNS's that NCYT should be at 2m a month by end of week and even with this manufacturing they can increase production further, on top of this they are looking at getting another manufacture on board to further increase production - "The Company also announces it is in advanced discussions with a second third-party manufacturer, based in the UK in order to further expand manufacturing capacity". Just gonna grow and grow over the coming months.
Yep I agree - remember that these guys were first for sars and ebola and now covid19. These guys don't hang around - small means there agile, and obviously these guys are very good at what they do, they just unfortunately needed this crisis to prove that. What else will they next be first on - remember they have a serology division too. Testing to see if you have the antibodies to see if you've previously had the virus.
Comical by name and investing, must try harder - wrong, wrong, wrong on every count - what is there production capability, they aren't even ready to produce till end of March, they have very few machines around the world that can work on their product which means they also have to produce that to sell. Have you checked their manufacturing capabilities - I thought not. This is a now now now situation. NCYT are with a few others but way ahead of the pack. They will make a mint, and so will holders, simple
It really doesn't matter if there are faster tests. NCYT's is fast. 2 hours is fast - what matters - NCYT's is 99.9% accurate. Even if you're 90% accurate that is a huge risk factor. % matter. Also its about distribution - NCYT deliver to over 60 countries and have the distributers to back it up. What also matters is having the stockpile to produce - NCYT have the ability to produce 5.5 million tests (note this has increased by 2m in the last 2 weeks - so they are stockpiling massively). Many of the competitors I've read up on are way behind that. What also matters is having the capability to mass produce. NCYT have increased production 10x and now added two more manufacturing products on there. 2m a month next week 2x that a couple of weeks later. Countries want delivery now - that 45min test isn't even ready to deliver to end of March and then somehow has to ramp up delivery to match that. Another thing that matters is regulated approval - well NCYT has the EU and now US FDA approval. And whilst we're on this it also matters being first, NCYT were first. And don't forget NCYT's product is compatible on the most common lab diagnostic equipment out there, available around the world. They basically have advantages everywhere, they are cheap, they are expanding massively in a growth sector where demand has probably never been so instantly high. If you can't see that, don't bother investing.
And there we have it JohnHenry, his last posts deramping, he's not bought in and changed full circle. Disgraceful, the same will happen with Midas, 9inch etc. They will announce some change in aspect that completely changed the companies circumstances with of course is complete BS and suddenly made them viable. The fact is this company over the coming months will be literally printing cash. They will be supplying to 60 countries, and like a stepping stone as this pandemic grows more in other countries (like it did from Italy to here), those 60+ countries will want more and more tests. Yes there will be others but it will be an expanding pie unfortunately.
Soup - markets look forward not at now - hence why shares are undervalued. SP reflects potential - hence why SOLG got to £500m mcap yet has yet to produce any revenue and there are so many examples like that. NCYT is actually not a jam tomorrow, the potential is just their staring investors in the face. Next week more news of growing sales, week after more growing sales etc Wham, wham, wham. At some point this will become a runaway train - hence why the derampers are getting desperate as they can see whats coming.